 |
TREATMENTS IN THE PIPELINE: 150 headlines |
|
|||||
My Educational Video on MS and MS Trials| Visitors Since 03/2006 |
||||||||||||||||||||||||||||||||||||||
| Our 670 MySpace Friends The New Face of MS |
||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||
| June 2006 | ||||||||||||||||||||||||||||||||||||||
| July 2006 | ||||||||||||||||||||||||||||||||||||||
| August 2006 | ||||||||||||||||||||||||||||||||||||||
| September 2006 | ||||||||||||||||||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||||||||||||||||||
| November 2006 | ||||||||||||||||||||||||||||||||||||||
Sunday
NEW MS DRUG: Biogen, Genentech See Solid Rituxan Data
NEW YORK (AP) - Drug makers Biogen Idec Inc. and Genentech Inc. said Monday a mid-stage study of Rituxan showed it was effective in treating MS.
The Food and Drug Administration originally approved the drug in 1997 for the treatment of cancer. It was developed by Cambridge, Mass-based Biogen and is co-marketed with South San Francisco, Calif-based Genentech in the United States.
The companies said the treatment reached its primary endpoint in reducing the number of gadolinium enhancing T1 lesions, or indicators of relapsing forms of MS, in a 104-patient study. The clinical trial compared Rituxan to a placebo and took place over 24 weeks.
Patients involved in the study will be followed for an additional 48 weeks as the companies monitor the long-term safety affects of the treatment.
MS, an autoimmune disease, is the leading cause of neurological disorders in young adults, the companies said, with the relapsing form of the disease accounting for 65 percent of all MS cases....."
NEW YORK (AP) - Drug makers Biogen Idec Inc. and Genentech Inc. said Monday a mid-stage study of Rituxan showed it was effective in treating MS.
The Food and Drug Administration originally approved the drug in 1997 for the treatment of cancer. It was developed by Cambridge, Mass-based Biogen and is co-marketed with South San Francisco, Calif-based Genentech in the United States.
The companies said the treatment reached its primary endpoint in reducing the number of gadolinium enhancing T1 lesions, or indicators of relapsing forms of MS, in a 104-patient study. The clinical trial compared Rituxan to a placebo and took place over 24 weeks.
Patients involved in the study will be followed for an additional 48 weeks as the companies monitor the long-term safety affects of the treatment.
MS, an autoimmune disease, is the leading cause of neurological disorders in young adults, the companies said, with the relapsing form of the disease accounting for 65 percent of all MS cases....."